The Next Generation Sequencing Market is estimated to be valued at US$12,870.5 million in 2023 and is expected to exhibit a CAGR Of 18.3% over the forecast period of 2022-2030, as highlighted in a new report published by Coherent Market Insights. Next-generation sequencing refers to high-throughput sequencing technologies that have revolutionized the field of genomic research. It enables researchers to analyze large amounts of genetic data rapidly and accurately, leading to advancements in various domains such as personalized medicine, oncology research, and agriculture. The market offers various products associated with next-generation sequencing, including instruments, consumables, and services.
The next-generation sequencing market is driven by multiple factors. Firstly, the increasing prevalence of chronic diseases and genetic disorders propels the demand for accurate and efficient sequencing technologies. Next-generation sequencing enables the identification of disease-related genetic mutations and aids in personalized medicine, driving market growth. Secondly, advancements in technology, such as the development of nanopore sequencing and single-cell sequencing, further enhance the capabilities of next-generation sequencing platforms, expanding their applications. These technological advancements lead to improved accuracy, reduced costs, and faster turnaround times, thus driving market adoption.
Market Key Trends:
The key trend in the Next Generation Sequencing (NGS) market is the increasing adoption of NGS technologies in various applications such as oncology, genetic diseases, and drug discovery. NGS offers high throughput sequencing, faster turnaround time, and cost-effectiveness compared to traditional sequencing methods. This has led to a growing demand for NGS in research and clinical settings. Additionally, advancements in NGS platforms, such as the development of portable and handheld NGS devices, are further driving market growth. These devices enable decentralized testing and point-of-care sequencing, which is particularly beneficial in resource-limited settings.
Strength: The NGS market is driven by the strong demand for personalized medicine and precision diagnostics. NGS enables comprehensive genomic profiling, allowing for the identification of genetic variations, disease-causing mutations, and personalized treatment plans.
Weakness: One of the key challenges in the NGS market is the high cost associated with equipment and consumables, which limits its adoption in certain regions and healthcare facilities. In addition, the complexity of data analysis and interpretation presents a bottleneck in the integration of NGS into routine clinical practice.
Opportunity: The increasing use of NGS in the field of liquid biopsy and non-invasive prenatal testing presents significant growth opportunities for the market. Liquid biopsy allows for the detection and monitoring of genetic alterations in circulating tumor DNA, while non-invasive prenatal testing enables the detection of fetal genetic abnormalities using maternal blood samples.
Threats: The NGS market faces competition from other sequencing technologies, such as Sanger sequencing and microarray analysis. Additionally, regulatory challenges and concerns regarding data privacy and security pose potential threats to market growth.
The Global NGS Market Demand is expected to witness high growth, exhibiting a CAGR of 18.3% over the forecast period. This growth is primarily driven by the increasing demand for personalized medicine, advancements in NGS platforms, and the expanding applications of NGS in oncology, genetic diseases, and drug discovery.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the NGS market due to the presence of major market players, well-established healthcare infrastructure, and high adoption rate of NGS technologies in research and clinical settings.
Key players operating in the NGS market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux SA, F. Hoffmann-La Roche Ltd, QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian. These key players have a strong market presence and are focused on technological advancements, strategic collaborations, and product launches to gain a competitive edge in the market.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it